Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects

AIMS: To evaluate pharmacokinetic equivalence and preliminary safety of the adalimumab biosimilar CT‐P17 administered via autoinjector (CT‐P17 AI) or prefilled syringe (CT‐P17 PFS) in healthy subjects. METHODS: This phase I, open‐label study (ClinicalTrials.gov: NCT04295356) randomised subjects (1:1...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Antonia, Brimhall, Darin, Kay, Jonathan, Keystone, Edward, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Choi, Eun Jin, Furst, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597139/
https://www.ncbi.nlm.nih.gov/pubmed/33822406
http://dx.doi.org/10.1111/bcp.14850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597139/
https://www.ncbi.nlm.nih.gov/pubmed/33822406
http://dx.doi.org/10.1111/bcp.14850

Ejemplares similares